SSM Health Saint Louis University Hospital recently performed the first transurethral ultrasound ablation (TULSA) procedure in Missouri as well as the larger Midwest region. It’s a minimally-invasive ...

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading ...

– TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – The positive perioperative results were ...

Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...

Profound Medical (PROF) announced the unveiling of its third TULSA-AI software module, UA Alignment Assistant, in addition to six presentations featuring the Transurethral Ultrasound Ablation ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

Aggressive. When he heard that word, Ken Richter knew he needed to act quickly. The Magnolia resident received his first cancer diagnosis in 2015 after a colonoscopy revealed an abnormal mass on his ...

TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...

ST. LOUIS – SSM Health Saint Louis University Hospital recently performed the first transurethral ultrasound ablation (TULSA) procedure in Missouri as well as the larger Midwest region. It’s a ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound ...